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Secondhand smoke (SHS) is a complex mix-
ture of chemicals generated by the burning 
of tobacco. SHS is associated with a number 
of adverse health effects, including chronic 
respiratory symptoms, lung cancer, and 
cardio vascular disease (CVD) [Barnoya and 
Glantz 2005; Centers for Disease Control and 
Prevention (CDC) 2006; Eisner and Iribarren 
2007; Ho et al. 2007; Panagiotakos et al. 2002; 
Raupach et al. 2006]. The American Heart 
Association (AHA) has determined that SHS 
is a cause of fatal CVD (Taylor et al. 1992). 
Smoking prevalence has declined among adults 
in the United States (CDC 2000, 2005); how-
ever, among the major blue-collar occupations 
(e.g., construction workers, motor vehicle 
opera tors, freight handlers, mechanics), it 
remains higher than those of many other occu-
pational groups (Bang and Kim 2001; Gerlach 
et al. 1997; Lee et al. 2007), suggesting that 
this is a popu lation with high potential for 
SHS exposure (Wortley et al. 2002).
Several studies of systemic inflammatory 
markers, which have been associated with sus-
ceptibility to CVD (Blake and Ridker 2002; 
Saadeddin et al. 2002; Tousoulis et al. 2007), 
have shown positive relationships with active 
smoking (Melbye et al. 2007; Saito et al. 
2003; Wannamethee et al. 2005). However, 
there is limited and inconsistent evidence of an 
association between SHS exposure and inflam-
matory markers (Clark et al. 2008; Cook et al. 
2000; Nagel et al. 2009; Panagiotakos et al. 
2004; Venn and Britton 2007). A study of 
adults in Greece (Panagiotakos et al. 2004) 
and another study of British elderly (Jefferis 
et al. 2010) without clinical evidence of CVD 
suggested that exposure to SHS is related to 
an increase in C-reactive protein (CRP) lev-
els, whereas this association was not found 
among never-smoking adults in the U.S. 
general population (Clark et al. 2008; Venn 
and Britton 2007). These studies have used 
either self-reports or biomarkers to assess 
SHS exposure. Cotinine in biological fluids 
has been used most widely as a biomarker 
(Benowitz 1999; CDC 2006). It is generated 
from nicotine in the liver and released into the 
bloodstream, and thus blood levels of cotinine 
should closely reflect the level of nicotine from 
inhaled SHS (Benowitz 1999). The average 
half-life of cotinine is about 17 hr, and coti-
nine levels remain relatively stable through-
out the day (Benowitz 1996). In the present 
study, we examined the relationship of SHS 
exposure meas ured by plasma cotinine with 
systemic inflammatory markers that included 
high-sensitivity CRP (hs-CRP) and inter-
leukin-6 (IL-6), and with soluble intercellular 
adhesion molecule-1 (sICAM-1), a marker of 
vascular endothelial activation and inflamma-
tion, among non smoking workers in the U.S. 
trucking industry. In addition, we evaluated 
the relationship between self-reported SHS 
exposure and plasma cotinine concentrations.
Materials and Methods
Study participants. Participants were from two 
volunteer groups of employees at unionized 
trucking companies in the United States in 
2007. For the first group, a total of 120 non-
smoking partici pants were recruited on-site 
among active workers at two work sites (truck-
ing terminals) located in Carlisle, Pennsylvania, 
and Chicago, Illinois (the on-site group). The 
second group of workers was recruited by mail 
from respondents to a health survey sent to a 
random sample of active and recently retired 
workers at three unionized companies (the 
mailing group). We invited these workers to 
provide blood samples and to complete an 
additional questionnaire. Of the 114 workers 
recruited by mail, 98 described themselves as 
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Background: Few studies have directly assessed the association of secondhand smoke (SHS) with 
cardiovascular disease–related inflammatory markers, and the findings are inconsistent. 
oBjectives: We assessed the association between SHS exposure and the inflammatory markers 
high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and soluble inter cellular adhesion 
molecule-1 (sICAM-1) in 199 non smoking U.S. trucking industry workers. 
Methods: Participants provided blood samples either by mail (blood drawn at local health care 
provider near home) or at the work site (blood drawn by research staff on-site) and completed a 
health and work history questionnaire at the time of blood draw. Exposure to SHS was measured by 
plasma cotinine concentrations. We used multivariate regression analyses to assess the associations 
between levels of cotinine and inflammatory markers. 
results: The median cotinine level was 0.10 ng/mL (interquartile range, 0.04–0.23 ng/mL). 
The odds ratios of elevated hs-CRP (above highest CRP tertile, 1.5 mg/L) were 2.85 [95% confi-
dence interval (CI), 1.03–7.89] for the high-cotinine group (> 0.215 ng/mL) and 2.80 (95% CI, 
1.11–7.10) for the moderate-cotinine group (0.05–0.215 ng/mL), compared with the low-cotinine 
group (< 0.05 ng/mL), adjusting for age, sex, race, educational level, obesity, previous smok-
ing history, job title, and medical history. Plasma cotinine levels were not associated with IL-6 
or sICAM-1. 
conclusions: SHS exposure, as assessed by plasma cotinine, was positively associated with hs-CRP 
in this group of blue-collar workers. The strength of the association with hs-CRP depended on the 
cut points selected for analysis.
key words: cardiovascular disease, CRP, IL-6, inflammatory marker, non smoker, occupational 
health, plasma cotinine, secondhand smoke, sICAM-1, trucking industry. Environ Health Perspect 
119:1294–1300 (2011). http://dx.doi.org/10.1289/ehp.1003199 [Online 31 May 2011]
SHS and inflammatory markers in nonsmoking truckers
Environmental Health Perspectives • volume 119 | number 9 | September 2011 1295
non smokers. The participants represented the 
major job categories in the trucking indus-
try: long-haul driver (driving between cities), 
pickup/delivery driver (local driving within 
cities), dock worker (moving freight within the 
trucking terminal), mechanic (repairing trac-
tors and trailers), hostler (moving trucks in the 
terminal yard), and clerk (office worker) (Smith 
et al. 2006). The protocol was approved by the 
human subjects committees at the Brigham 
and Women’s Hospital, the Harvard School of 
Public Health, and the Veterans Affairs Boston 
Healthcare System, and each participant pro-
vided informed consent before participating.
Blood sample collection. For those who 
were recruited via mail, a blood kit contain-
ing four 10-mL liquid EDTA blood tubes, a 
freezer pack, and detailed instructions were 
sent to their households. The participants were 
asked to go to their local health care provider or 
a walk-in clinic to have approximately 30 mL 
of blood drawn. They then sent the blood with 
a coolant to our laboratory by over night ship-
ment. The mailing protocols were developed 
from the methods used in previous large epi-
demiologic studies that successfully collected 
the blood samples by mail (Pischon et al. 2003; 
Ridker et al. 1997). Workers recruited on-site 
at the trucking terminals had their blood drawn 
by our research team and provided blood sam-
ples before, during, or after their work shift 
during the sampling week. These blood sam-
ples were also sent back to the laboratory by 
overnight shipping every day. Upon arrival, 
the chilled blood samples were centrifuged in a 
refrigerated unit, and blood components were 
aliquoted in cryotubes, which were stored in 
liquid nitrogen freezers at less than –130°C.
SHS and health questionnaire. Participants 
completed a health questionnaire, provid-
ing information regarding their exposure to 
SHS and previous smoking history. Detailed 
information about demographic characteristics 
and life style, including age, sex, race/ethnicity, 
educational level, height and weight, job title 
and work history, time of blood draw, alcohol 
intake, physical activity, medical history, and 
medication use, was also obtained. Participants 
recruited by mail were asked to complete the 
questionnaire on the day of their blood draw 
and send it back to us along with the blood 
kit. Participants recruited on-site were asked 
to complete the questionnaire at the time of 
blood draw. Job title was categorized into four 
groups: drivers, terminal workers (including 
terminal dock workers and hostlers), office 
workers, and retired.
Assessment of SHS exposure by plasma 
cotinine. SHS exposure of the workers was 
assessed by plasma cotinine levels. Cotinine 
analysis was conducted in the clinical pharma-
cology laboratory at San Francisco General 
Hospital Medical Center. Concentrations of 
cotinine in plasma were measured by liquid 
chromatography/tandem mass spectrometry 
(Bernert et al. 1997). The limit of quantita-
tion (LOQ) was 0.02 ng/mL. Of 218 samples 
analyzed, 199 (91.3%) were > LOQ. Samples 
< LOQ (n = 19) were assigned a value of 
0.014 ng/mL (the LOQ divided by the square 
root of 2) by the laboratory. The measurement 
of plasma cotinine generally reflects SHS expo-
sure in the previous 1–2 days (Benowitz 1996).
Only workers with plasma cotinine levels 
≤ 14 ng/mL were considered non smokers, 
because a person with a plasma cotinine level 
> 14 ng/mL is generally considered to be a 
smoker (Jarvis et al. 1987). Of 218 workers 
who reported no current cigarette, cigar, or 
pipe smoking, 199 (91%; 94 recruited by 
mail and 105 on-site) had cotinine levels 
≤ 14 ng/mL and were eligible for our statisti-
cal analysis. None of the participants reported 
taking nicotine replacement therapy.
Assessment of inflammatory markers. The 
analyses of inflammatory markers were per-
formed at the Clinical and Epidemiologic 
Research Laboratory,  Department of 
Laboratory Medicine, at Children’s Hospital 
(Boston, MA). CRP levels were determined 
by an immuno turbidi metric assay on a 
Hitachi 917 analyzer (Roche Diagnostics, 
Indianapolis, IN), using reagents and cali-
brators from Denka Seiken (Niigata, Japan). 
Concentrations of sICAM-1 and IL-6 were 
measured by enzyme-linked immunosorbent 
assays (ELISA), using the quantitative sand-
wich enzyme immuno assay technique (R&D 
Systems, Minneapolis, MN). For the three 
inflammatory markers analyzed, all the sam-
ples were above the laboratory thresholds of 
detection (0.03 mg/L for CRP, 0.094 pg/mL 
for IL-6, and 0.35 ng/mL for sICAM-1). The 
day-to-day variability of the analytic assay was 
2.81% for CRP, 7.2% for IL-6, and 6.0% for 
sICAM-1. The Spearman’s correlation coef-
ficient was 0.43 (p < 0.01) for CRP and IL-6, 
0.35 (p < 0.01) for CRP and sICAM-1, and 
0.21 (p < 0.01) for IL-6 and sICAM-1.
Statistical analysis. To evaluate the rela-
tionship between self-reported SHS exposure 
and plasma cotinine levels, we used linear 
regression analysis with adjustment for con-
founders. Because the residuals of this regres-
sion model were right-skewed, we used the 
robust variance for statistical inference (White 
1980). We compared demographics, health- 
related charac teristics, and inflammatory 
marker levels across three categories of plasma 
cotinine: < LOQ (< 0.02 ng/mL), low cotinine 
(0.02–0.11 ng/mL, the median value among 
those with quantifiable levels), and high coti-
nine (> 0.11 ng/mL). To determine if the 
levels of the inflammatory markers were dif-
ferent across demographic and health-related 
charac teristics groups, we used multi variate 
linear regression analyses with robust variance, 
adjusting for potential confounders.
To assess the association between plasma 
cotinine and the inflammatory markers, we 
performed a) multi variate linear regression 
analyses, using robust variance, with inflamma-
tory markers modeled as continuous dependent 
variables; and b) multi variate logistic regression 
analyses with inflammatory markers classi fied 
as dichotomous outcomes. Because there is 
no established cut point for defining heavy 
SHS exposure versus light SHS exposure, we 
explored several different cut-points for catego-
rizing plasma cotinine. First, plasma cotinine 
was categorized into three groups (< LOQ, 
low, or high), as described above. In addi-
tion, we categorized cotinine using cut-points 
from a study of Third National Health and 
Nutrition Examination Survey (NHANES III) 
data as low (< 0.05 ng/mL, the detection limit 
of analytic method used in early NHANES 
III), medium (0.05–0.215 ng/mL, the median 
value among those above the detection limit in 
that study), or high (> 0.215 ng/mL) (Venn 
and Britton 2007). Tests for linear trend were 
performed using the median value for each 
cate gory of cotinine. Finally, we also consid-
ered a cut-point of plasma cotinine derived 
from a receiver operating charac teristic (ROC) 
curve (Fawcett 2006) based on self-reported 
SHS exposure. The ROC curve was gener-
ated by calculating sensitivity and specificity of 
each cotinine level in our data set, where the 
sensitivity represents the percentage of workers 
categorized as high cotinine among those who 
reported that they were exposed to SHS in the 
previous day, and the specificity represents the 
percentage of workers categorized as low coti-
nine among those who reported that they were 
not exposed to SHS in the previous day. The 
selected cut-point that maximized the specific-
ity with a sensitivity > 70% was 0.06 ng/mL. 
We considered covariates that were either bio-
logically meaningful potential confounders or 
statistically significant in univariate analyses: 
socio demographics (age, sex, race, educational 
level), job title, recruitment method, former 
smoking, body mass index (BMI; weight in 
kilograms divided by height in meters squared), 
and medical conditions [high blood pressure, 
history of heart disease, chronic obstructive 
pulmonary disease (COPD), chronic rhinitis, 
hay fever]. We also examined effect modifica-
tion by age, BMI, and former smoking status 
by fitting inter action terms and performing 
stratified analyses. All p-values are two sided, 
and statistical significance was determined for 
an α-level of 0.05.
In logistic regression analyses, we used the 
median levels of each inflammatory marker as 
the cut-points of elevated versus nonelevated 
outcome variables. Additionally, the CDC and 
AHA suggest that the measure ment of CRP in 
the adult population be categorized into tertiles 
(Pearson et al. 2003), because meta- analyses 
of several population-based prospective studies 
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found that the risk of future CVD is doubled 
in subjects with hs-CRP in the study-specific 
highest tertile compared with the lowest tertile 
(Danesh et al. 1998, 2000; Pearson et al. 2003). 
Therefore, we also assessed the risk of being in 
the highest tertile of hs-CRP, while combining 
the lower two tertiles as the reference group 
to increase the sample size. All analyses were 
performed with SAS statistical software (ver-
sion 9.1.3; SAS Institute Inc., Cary, NC).
Results
Participant characteristics. Table 1 presents 
partici pant characteristics, as well as lev-
els of cotinine and inflammatory markers, 
by SHS exposure group. Overall, the demo-
graphic charac teristics of the workers were 
similar across the exposure groups. However, 
the workers recruited by mail were older 
(mean age, 60 years), thinner (median BMI, 
27.8 kg/m2), less likely to report SHS expo-
sure in the past 24 hr (36%), and more likely 
to report COPD (12%) and chronic rhinitis 
(14%), compared with those recruited on-site 
(mean age, 51 years; median BMI, 29.8 kg/m2; 
SHS in the past 24 hr, 68%; COPD, 5%; 
chronic rhinitis, 2%).
Self-reported SHS exposure and plasma 
cotinine levels. The mean ± SD and the median 
[interquartile range (IQR)] cotinine levels 
were 0.30 ± 0.60 ng/mL and 0.10 (0.04–0.23) 
ng/mL for all 199 workers (Table 1). As 
expected, workers who reported that they were 
exposed to SHS in the past 24 hr had higher 
plasma cotinine concentrations [median 
(IQR), 0.18 (0.05–0.42) ng/mL] than those 
who reported no recent SHS exposure [0.07 
(0.04–0.12) ng/mL; Wilcoxon rank-sum test 
p < 0.001]. After controlling for age, sex, race, 
educational level, former smoking, recruit-
ment method, job title/work status, and the 
time of blood draw, self-reported SHS expo-
sure in the past 24 hr was associated with a 
0.31 ng/mL (95% CI = 0.16–0.46 ng/mL) 
higher cotinine level.
Predictors of inflammatory markers. 
Levels of inflammatory markers by all poten-
tial confounders are shown in Table 2. The 
mean ± SD and the median (IQR) hs-CRP 
concentrations were 1.71 ± 2.13 mg/L and 
0.93 (0.46–2.06) mg/L. Only one partici-
pant had a CRP level > 10 mg/L, a level sug-
gested as an indicator of infection (Tousoulis 
et al. 2007), suggesting that most of the par-
ticipants did not have recent infections before 
the blood draw. The mean ± SD and the 
median (IQR) levels were 2.36 ± 3.18 pg/mL 
and 1.38 (1.02–2.58) pg/mL for IL-6, and 
250.9 ± 68.3 ng/mL and 246.1 (203.2–
284.4) ng/mL for sICAM-1. The median 
levels of hs-CRP, IL-6, and sICAM-1 were 
0.92 mg/L, 1.42 pg/mL, and 233.2 ng/mL, 
respectively, for those recruited on-site and 
0.95 mg/L, 1.24 pg/mL, and 256.7 ng/mL for 
those recruited by mail.
The results from multi variate linear regres-
sion analysis also revealed other important 
significant predictors of inflammatory mark-
ers, including obesity (BMI ≥ 30 kg/m2, for all 
three markers), former smoking (for hs-CRP), 
COPD (for hs-CRP and sICAM-1), ≥ 60 years 
of age (for IL-6), and Caucasian (for IL-6) 
(data not shown). The multi variate-adjusted 
odds ratio (OR) of high CRP (highest tertile) 
comparing participants who reported that they 
were exposed to SHS with those who reported 
no SHS exposure in the past 24 hr was posi-
tive but not significant [OR = 1.10 (95% CI, 
0.51–2.35)].
Plasma cotinine and inflammatory 
 markers. In the multi variate linear regression 
analyses assessing the relationship between 
continuous levels of plasma cotinine and each 
inflammatory marker, we found no statisti-
cally significant evidence of a positive lin-
ear association after controlling for age, sex, 
race, educational level, job title/work status, 
recruitment method, former smoking, obesity, 
high blood pressure, history of heart disease, 
COPD, chronic rhinitis, and hay fever (data 
not shown). In the multi variate logistic regres-
sion adjusted for the same covariates listed 
above, we found a positive but not statistically 
significant association between SHS exposure, 
as defined by continuous cotinine levels, and 
elevated (highest tertile vs. others) hs-CRP 
(OR = 1.15; 95% CI, 0.95–1.39, associated 
with a doubling in cotinine concentration). 
Table 3 presents the results from multivariate-
adjusted logistic regression models using the 
different exposure cut-points, where we also 
observed a suggestive independent positive 
relationship between categorical cotinine and 
hs-CRP. However, the results varied based 
on the cut-points of plasma cotinine used. In 
addition, when we defined “elevated hs-CRP” 
as being in the highest tertile, we observed a 
stronger and significant positive association 
with cotinine levels > 0.05 ng/mL. Overall, we 
found no evidence of a significant association 
of plasma cotinine with IL-6 or sICAM-1, 
including when we explored other cut-points 
such as the highest tertile. 
We found some evidence of effect mod-
ification by obesity from stratified analyses, 
although the inter action between obesity and 
cotinine was not statistically significant (p for 
interaction = 0.49). The OR (95% CI) of 
elevated CRP (highest tertile) comparing the 
high-cotinine (> 0.06 ng/mL) group with the 
low-cotinine group was much higher in obese 
workers [n = 77; OR = 6.65 (1.55–28.6)] than 
in non obese workers [n = 122; OR = 1.51 
(0.43–5.24)]. We found no statistically 
Table 1. Levels of plasma cotinine and inflammatory markers, and characteristics of 199 nonsmoking 
workers in the U.S. unionized trucking industry.
Exposure group 
Variable 
All subjects  
(n = 199)
Below LOQ  
(n = 19)
Low cotinine  
(n = 90)
High cotinine  
(n = 90)
Continuous variables [median (IQR)]
Cotinine (ng/mL) 0.10 (0.04–0.23) N/A 0.05 (0.04–0.08) 0.26 (0.18–0.59)
CRP (mg/L) 0.93 (0.46–2.06) 0.93 (0.43–1.53) 1.02 (0.52–1.97) 0.87 (0.43–2.09)
IL-6 (pg/mL) 1.38 (1.02–2.58) 1.16 (1.04–2.05) 1.43 (1.02–3.01) 1.36 (1.02–2.26)
sICAM-1 (ng/mL) 246.1 (203.2–284.4) 288.5 (231.1–321.7) 240.5 (202.3–283.4) 243.7 (200.7–281.2)
Age (years) 57 (49–62) 58 (46–62) 57 (51–63) 55 (47–60)
BMI (kg/m2)a 28.8 (25.8–33.1) 27.4 (25.5–31.2) 29.0 (26.0–33.7) 28.9 (26.6–32.1)
Categorical variablesb [n (%)]
Male 183 (92.0) 16 (84.2) 81 (90.0) 86 (95.6)
Caucasian 183 (92.0) 16 (84.2) 85 (94.4) 82 (91.1)
Education > 12 years 71 (35.7) 9 (47.4) 30 (33.3) 32 (35.6)
SHS in previous 24 hr 105 (52.8) 9 (47.4) 34 (37.8) 62 (68.9)
Former smoker 98 (49.3) 10 (52.6) 43 (47.8) 45 (50.0)
Alcohol use in previous 24 hra 43 (21.6) 3 (15.8) 21 (23.3) 19 (21.1)
Job title
Office worker 18 (9.1) 5 (26.3) 7 (7.8) 6 (6.7)
Terminal worker 58 (29.1) 6 (31.6) 21 (23.3) 31 (34.4)
Driver 97 (48.7) 5 (26.3) 44 (48.9) 48 (53.3)
Retired 26 (13.1) 3 (15.8) 18 (20.0) 5 (5.6)
Medical condition 
Heart problem/disease 24 (12.1) 3 (15.8) 10 (11.1) 11 (12.2)
High blood pressurea 59 (29.7) 3 (15.8) 30 (33.3) 26 (28.9)
Asthmaa 20 (10.1) 2 (10.5) 11 (12.2) 7 (7.8)
COPD 16 (8.0) 3 (15.8) 8 (8.9) 5 (5.6)
Chronic rhinitisa 15 (7.5) 2 (10.5) 9 (10.0) 4 (4.4)
Hay fevera 43 (21.6) 3 (15.8) 26 (28.9) 14 (15.6)
Aspirin use 62 (31.2) 6 (31.6) 34 (37.8) 22 (24.4)
Exposure groups are defined by plasma cotinine levels as follows: Below LOQ, < 0.02 ng/mL; Low cotinine, 0.02–0.11 ng/mL; 
High cotinine, > 0.11 ng/mL.
aMissing values: BMI (n = 1), alcohol use in last 24 hr (n = 20), high blood pressure (n = 3), asthma (n = 3), chronic rhinitis 
(n = 6), hay fever (n = 5). bInformation obtained from participants’ self-reports. 
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significant evidence of effect modification by 
age, sex, and former smoking (data not shown). 
We also performed an analysis restricted to the 
workers recruited on-site (n = 105), because 
these workers were all currently working. In 
addition, detailed information on other poten-
tial confounders, including physical activity 
and use of cholesterol control medicine, was 
available only for this group. The results were 
similar to the multi variate logistic regression 
analyses performed for all participants, and 
additional inclusion of these potential con-
founders did not alter the results. Similarly, 
the conclusions from the models restricted to 
males (n = 183) did not differ from the final 
model including both males and females (data 
not shown). Furthermore, because recent 
infections or illness might increase the CRP 
level (Tousoulis et al. 2007), we performed an 
analysis restricted to participants who did not 
report a recent illness (n = 182), and an analy-
sis excluding one participant whose CRP was 
> 10 mg/L. The results were consistent with 
analyses for the population as a whole.
Discussion
In this population of non smoking blue-collar 
trucking industry workers, we observed evi-
dence of an association between plasma coti-
nine levels and elevated hs-CRP, but not IL-6 
or sICAM-1. Self-reported SHS exposure in 
the past 24 hr was significantly positively asso-
ciated with increased level of plasma cotinine, 
indicating that self-reported SHS exposure 
was reliable in this population.
A few previous studies have examined 
the association between SHS exposure and 
CRP, with inconsistent results. In studies 
of NHANES III, no significant association 
was found between CRP and serum cotinine 
levels in never-smokers in the U.S. general 
population (Venn and Britton 2007) or non-
smoking adult workers without home SHS 
exposure (Clark et al. 2008). On the other 
hand, in an analysis of Greek adults who 
had never smoked (n = 995), Panagiotakos 
et al. (2004) reported a 0.8 mg/L (p = 0.03) 
increase of CRP for those regularly exposed 
to SHS (> 3 days/week for at least 30 min/
day), compared with those who were not 
exposed. In another study, Jefferis et al. (2010) 
investigated about 5,000 non smoking British 
elderly and observed a significant association 
between serum cotinine and CRP in a lin-
ear regression model adjusted for age, sex, 
region of residence, health behaviors, social 
class, and BMI (β = 0.03; 95% CI, 0.01–0.05; 
difference of natural log– transformed CRP 
associated with a doubling in cotinine con-
centration). The results from the present study 
suggest that higher plasma cotinine levels 
(> 0.05 ng/mL) may be associated with ele-
vated CRP (> 1.5 mg/L). The analytic method 
for CRP used in our study is a high-sensitivity 
immuno assay with a detection limit of 
0.03 mg/L, compared with 3 mg/L (Venn 
and Britton 2007) and 0.1 mg/L (Clark et al. 
2008) in the NHANES III studies.
To our knowledge, the association 
between SHS exposure and IL-6 was inves-
tigated previously only in a study of British 
elderly (Jefferis et al. 2010). In multivariate-
adjusted linear regression, that study showed 
a marginally significant positive association 
between log-transformed IL-6 and cotinine 
(β = 0.01; 95% CI, 0.00–0.02; associated 
with a doubling in cotinine concentration), 
whereas our study did not show this asso-
ciation. No previous studies have estimated 
the effect of SHS exposure on sICAM-1, 
and we did not observe an association in 
the present study. Other markers of inflam-
mation, such as homo cysteine and fibrino-
gen, have been associated with serum 
cotinine levels (Clark et al. 2008; Jefferis 
et al. 2010; Panagiotakos et al. 2004; Venn 
and Britton 2007). It is possible that the 
bio markers of inflammation that we examined 
are less sensitive to low level SHS exposure 
than are homocysteine and fibrinogen.
Table 2. Levels of inflammatory markers [median (IQR)] by demographic, work-related, and health-related 
variables.
Variable n hs-CRP (mg/L) IL-6 (pg/mL) sICAM-1 (ng/mL)
Age (years)
≤ 50 57 0.83 (0.43–1.90) 1.22 (0.84–2.05) 239.7 (202.3–282.8)
50–60 76 0.84 (0.44–1.84) 1.41 (1.08–2.42) 245.4 (198.7–297.0)
 > 60 66 1.14 (0.63–2.45) 1.64 (1.05–3.39) 252.2 (214.8–283.4)
Sex 
Female 16 1.48 (0.86–3.96) 1.39 (0.99–2.48) 277.5 (237.8–328.2)
Male 183 0.91 (0.44–1.92) 1.38 (1.02–2.66) 242.4 (201.3–284.3)
Race
Non-Caucasian 16 0.99 (0.47–3.41) 1.32 (0.83–1.83) 260.0 (190.9–297.0)
Caucasian 183 0.93 (0.46–1.96) 1.38 (1.04–2.66) 246.0 (203.7–284.3)
Education (years)
≤ 12 128 0.98 (0.46–2.13) 1.32 (0.93–2.73) 242.0 (200.3–281.8)
 > 12 71 0.83 (0.46–1.72) 1.44 (1.07–2.25) 254.2 (208.0–291.6)
BMIa
Normal 27 0.71 (0.42–1.13) 1.31 (0.87–1.98) 241.6 (230.9–276.6)
Overweight 95 0.73 (0.42–1.42) 1.18 (0.88–2.05) 239.4 (199.4–279.3)
Obese 77 1.91 (0.84–3.65) 1.86 (1.16–3.60) 260.9 (208.1–301.1)
Smoking history
Never 101 0.76 (0.42–1.69) 1.21 (0.88–2.05) 239.7 (199.0–276.6)
Former 98 1.28 (0.68–2.52) 1.73 (1.11–3.10) 255.8 (207.8–299.8)
Alcohol use in previous 24 hr
No 136 0.98 (0.50–2.08) 1.44 (1.10–2.69) 247.7 (207.6–284.4)
Yes 43 0.73 (0.32–1.73) 1.38 (0.84–2.70) 238.9 (197.8–283.4)
Job title
Office worker 18 1.00 (0.82–1.96) 1.31 (1.05–1.86) 282.3 (239.0–321.7)
Terminal worker 58 0.87 (0.46–1.64) 1.18 (0.88–2.10) 234.6 (203.6–268.0)
Driver 97 0.91 (0.42–1.97) 1.42 (1.03–2.99) 244.6 (198.4–283.6)
Retired 26 1.14 (0.72–2.57) 1.74 (1.18–3.52) 252.4 (214.8–306.6)
Recruitment group
On-site 105 0.92 (0.43–2.09) 1.42 (1.03–2.66) 233.2 (197.8–273.5)
By mail 94 0.95 (0.55–1.96) 1.24 (1.01–2.57) 256.7 (217.7–299.8)
COPD
No 183 0.86 (0.44–1.88) 1.34 (0.96–2.48) 241.6 (202.0–282.8)
Yes 16 2.49 (1.41–4.27) 1.81 (1.18–4.25) 319.3 (266.7–344.0)
Asthma
No 179 0.91 (0.44–1.91) 1.34 (1.02–2.47) 242.8 (202.3–282.8)
Yes 20 1.89 (0.79–2.37) 1.95 (1.17–4.13) 283.9 (222.0–339.6)
Chronic rhinitis
No 184 0.92 (0.45–1.95) 1.32 (0.98–2.48) 242.0 (203.1–284.0)
Yes 15 1.86 (0.71–2.17) 2.15 (1.65–2.91) 274.3 (242.8–316.9)
High blood pressure
No 140 0.82 (0.44–1.88) 1.22 (0.88–2.07) 242.6 (202.6–284.0)
Yes 59 1.38 (0.71–2.68) 2.05 (1.16–3.34) 256.6 (217.2–314.1)
Heart problem/disease
No 175 0.93 (0.46–1.96) 1.32 (1.02–2.48) 241.6 (202.3–281.2)
Yes 24 1.18 (0.54–2.41) 2.07 (1.08–4.62) 287.0 (210.6–358.9)
Hay fever
No 156 0.90 (0.45–1.90) 1.36 (1.03–2.65) 246.8 (205.1–289.9)
Yes 43 1.22 (0.50–2.16) 1.40 (0.88–2.48) 231.2 (202.0–282.8)
Aspirin use
No 137 0.93 (0.46–1.91) 1.34 (1.04–2.48) 242.4 (200.7–282.8)
Yes 62 0.89 (0.46–2.37) 1.41 (0.92–2.91) 254.2 (208.0–290.2)
aNormal, < 25 kg/m2; overweight, 25–29.9 kg/m2; obese, ≥ 30 kg/m2.
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Our findings that plasma cotinine may be 
associated with CRP but not with the other two 
inflammatory markers may partially be explained 
by the stability of each measured biomarker. 
CRP has a half-life of about 19 hr (Koenig 
et al. 2003), similar to that of plasma cotinine 
(Benowitz 1996), and may require an induc-
tion time of 1–2 days after an acute inflamma-
tory stimulus (Rückerl et al. 2007). Therefore, 
an elevation in CRP may reflect SHS exposure 
about 2–3 days before, which is close to the 
suggested exposure period corresponding to 
meas ured plasma cotinine (Benowitz 1999). 
On the other hand, IL-6 has a shorter half-life 
(2–6 hr) (Riches et al. 1992) and likely reflects 
a more immediate response. There is limited 
information to date on sICAM-1 to make an 
inference of the exposure–response time line. 
It is possible that plasma cotinine may not be 
an appropriate measure ment to determine if an 
association exists between SHS exposure and 
IL-6 or sICAM-1.
One potential problem in studies examin-
ing health effects among non smokers is that 
smokers might be mis classified as non smokers 
and included in the study population. We 
used 14 ng/mL as the cut-point of plasma 
cotinine levels for distinguishing smokers from 
non smokers, as suggested previously by Jarvis 
et al. (1987). Recently, Benowitz et al. (2009) 
suggested that this definition might over-
estimate the number of non smokers and that 
the cut-point should be lowered and be spe-
cific to sex and race/ethnicity. They proposed 
an optimal cut-point of 6.79 ng/mL for adult 
non-Hispanic white males, most of our study 
population. In the present study, after exclud-
ing workers with cotinine levels > 14 ng/mL, 
the maximum level of plasma cotinine meas-
ured in our study population was 4.44 ng/mL, 
which is well below this optimal cut-point. 
Thus, those defined as non smokers in our 
study would still have been identified as non-
smokers even with this lower cut-point.
To our knowledge, there is no well-estab-
lished cut-point of cotinine for high/heavy 
SHS exposure versus low/light SHS exposure. 
Previous studies have used median levels or 
levels of detection as cutoffs (Clark et al. 2008; 
Venn and Britton 2007), which are specific 
to the study population and the laboratory 
analytic methods. In our study, we explored 
the association between plasma cotinine and 
inflammatory markers using several differ-
ent cotinine cut-points, including the LOQ 
(0.02 ng/mL), the median value, and an opti-
mal cutoff chosen from a ROC curve based 
on data from our population, and cut-points 
used in previous studies of NHANES III data 
(Clark et al. 2008; Venn and Britton 2007). 
Although the ORs of elevated hs-CRP were 
positive when 0.02 ng/mL was used as the cut-
point for the low cotinine group, this effect 
estimate was not statistically significant, prob-
ably because this cut-point is too low and the 
group size is too small. The ROC cut-points 
and the NHANES cut-points seemed to pro-
duce consistent results, possibly at least in part 
because of the similar cut-points for the ref-
erence exposure group. Although exploring 
different cutoffs could increase the possibility 
of observing an association due to chance, we 
found a consistent pattern of a positive associ-
ation between cotinine and CRP levels across 
all the analyses regardless of the cutoffs.
Previous studies have derived some clini-
cal cut-points for CRP. It has been suggested 
that a person is at low risk of CVD if CRP is 
< 1 mg/L, average risk if CRP is 1–3 mg/L, 
and high risk if CRP is > 3 mg/L, and these 
cut-points approximately correspond to ter-
tiles of CRP levels in the general population 
of U.S. adults (Pearson et al. 2003; Tousoulis 
et al. 2007). In addition, a meta-analysis of 
a list of prospective studies showed that sub-
jects in the highest tertile (study-specific cut-
points) of hs-CRP in general had twice the 
relative risk of major coronary events than 
Table 3. Cotinine levels in relation to elevated inflammatory markers in nonsmoking U.S. trucking industry 
workers.
Inflammatory marker/cotinine level
Multivariate adjusteda 
n OR (95% CI) p-Value for trend
hs-CRP (> median vs. ≤ median)b 
Truck industry
Below LOQ, < 0.02 ng/mL 19 Reference 0.84
Low, 0.02–0.11 ng/mL 90 1.05 (0.32–3.48)
High, > 0.11 ng/mL 90 1.12 (0.33–3.84)
NHANES III
Low, < 0.05 ng/mL 65 Reference 0.80
Moderate, 0.05–0.215 ng/mL 79 1.78 (0.77–4.09)
High, > 0.215 ng/mL 55 1.43 (0.57–3.60)
ROC curve
Low, ≤ 0.06 ng/mL 73 Reference 0.08
High, > 0.06 ng/mL 126 1.99 (0.92–4.30)
hs-CRP (highest tertile vs. others)c 
Truck industry
Below LOQ, < 0.02 ng/mL 19 Reference 0.21
Low, 0.02–0.11 ng/mL 90 1.18 (0.31–4.59)
High, > 0.11 ng/mL 90 1.88 (0.48–7.35)
NHANES III
Low, < 0.05 ng/mL 65 Reference 0.17
Moderate, 0.05–0.215 ng/mL 79 2.80 (1.11–7.10)
High, > 0.215 ng/mL 55 2.85 (1.03–7.89)
ROC curve
Low, ≤ 0.06 ng/mL 73 Reference 0.02
High, > 0.06 ng/mL 126 2.72 (1.16–6.37)
IL-6 (> median vs. ≤ median)d 
Truck industry
Below LOQ, < 0.02 ng/mL 19 Reference 0.70
Low, 0.02–0.11 ng/mL 90 1.12 (0.35–3.65)
High, > 0.11 ng/mL 90 0.94 (0.28–3.14)
NHANES III
Low, < 0.05 ng/mL 65 Reference 0.94
Moderate, 0.05–0.215 ng/mL 79 1.60 (0.69–3.71)
High, > 0.215 ng/mL 55 1.21 (0.49–2.99)
ROC curve
Low, ≤ 0.06 ng/mL 73 Reference 0.18
High, > 0.06 ng/mL 126 1.70 (0.78–3.70)  
sICAM-1 (> median vs. ≤ median)e 
Truck industry
Below LOQ, < 0.02 ng/mL 19 Reference 0.61
Low, 0.02–0.11 ng/mL 90 0.48 (0.15–1.53)
High, > 0.11 ng/mL 90 0.70 (0.21–2.26)
NHANES III
Low, < 0.05 ng/mL 65 Reference 0.15
Moderate, 0.05–0.215 ng/mL 79 1.32 (0.60–2.91)
High, > 0.215 ng/mL 55 0.66 (0.28–1.55)
ROC curve
Low, ≤ 0.06 ng/mL 73 Reference 0.80
High, > 0.06 ng/mL 126 1.10 (0.54–2.22)
Exposure cut-points for NHANES III are from Venn and Britton (2007); those for the ROC curve were calculated following 
the method of Fawcett (2006).
aLogistic regression model adjusted for age, sex, race, educational level, job title, recruitment method, former smoking, 
obesity, high blood pressure, history of heart disease, COPD, chronic rhinitis, and hay fever. bhs-CRP median, 0.93 mg/L. 
chs-CRP highest tertile, > 1.5 mg/L. dIL-6 median, 1.38 pg/mL. esICAM-1 median, 246.1 ng/mL.
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those in the lowest tertile (Danesh et al. 1998, 
2000). Thus, the CDC/AHA suggested that 
the measurement of CRP in the adult popula-
tion be stratified into three tertiles (Pearson 
et al. 2003; Tousoulis et al. 2007). However, 
there are no well-established cut-points for 
sICAM-1 or IL-6. In the present study, the 
median of hs-CRP was 0.93 mg/L, which 
was close to 1 mg/L, the clinical cut-point of 
average risk of CVD versus low risk of CVD. 
To be consistent, we also used the median 
as a cut-point for sICAM-1 and IL-6 in our 
analyses. In addition, we explored different 
clinical cut-points of hs-CRP suggested by the 
studies mentioned above. We found a stron-
ger association between SHS exposure and 
hs-CRP when we compared the highest tertile 
of hs-CRP with the lower two tertiles.
Our study has several potential limita-
tions. The measure ment of plasma cotinine 
generally reflects the SHS exposure in the pre-
vious 1–2 days and might not represent more 
acute or more chronic exposures if the expo-
sure is largely variable. Previous studies have 
suggested that IL-6 levels have a large daily 
variability (Tousoulis et al. 2007), whereas 
sICAM-1 and CRP do not (Mosevold and 
Bruserud 2002; Osmancik et al. 2004; 
Tousoulis et al. 2007). It is possible that we 
did not completely account for the circadian 
variation, but the results of our analyses were 
unchanged when the time of blood draw (i.e., 
morning, afternoon, evening, overnight) was 
included in our regression models (data not 
shown). Our data came from two recruitment 
sources. Members of the mailing group had 
their blood samples collected independently 
using protocols developed for large epidemio-
logic studies (e.g., the Nurses’ Health Study) 
and returned them by express mail (Pischon 
et al. 2003; Ridker et al. 1997). The blood 
from the on-site group was collected by our 
study team and similarly express mailed to our 
laboratory for processing. Despite these collec-
tion differences, the distributions of inflam-
matory markers were similar between the two 
recruitment groups (Table 2). We also con-
trolled for participant characteristics and the 
recruitment method in all of the multi variate 
regression analyses. In addition, the results 
from the sensitivity analyses restricted to the 
on-site group were similar to the findings of 
the analyses performed for all participants.
The range of plasma cotinine and some 
covariates (e.g., BMI, age) we observed in this 
study was relatively narrow compared with 
the NHANES III studies, so we might have 
missed the association between SHS exposure 
and inflammatory markers because of non-
differential mis classifi ca tion. Nevertheless, 
we used high-sensitivity laboratory analytic 
methods for both plasma cotinine and inflam-
matory markers, minimizing the chance of mis-
classification for both exposure and outcome. 
The sample size of our study was small, lead-
ing to the possibility of insufficient power to 
detect some potentially significant differences. 
Moreover, other occupational exposures, such 
as diesel exhaust, may confound or modify the 
association of SHS exposure with the inflam-
matory markers. However, we adjusted for job 
title, a reasonable indicator of occupational 
exposure to air pollutants in these trucking 
companies (Smith et al. 2006). Measurements 
of some conventional biomarkers related 
to coronary heart disease, such as lipid lev-
els (low-density lipoprotein, high-density 
lipoprotein, and triglycerides), were not avail-
able for our study. However, these are unlikely 
to confound the association between SHS and 
inflammatory markers because it is unlikely 
that these factors would be an antecedent 
or a proxy marker of an antecedent of SHS. 
Although information on a history of heart 
problems and high blood pressure was based 
on self-report, as opposed to medical records or 
direct measurements, workers in these truck-
ing companies are required to pass a physi-
cal examination conducted every 1–2 years in 
order to continue working, and health con-
ditions such as high blood pressure and any 
heart diseases have to be treated. Some retired 
workers were recruited by mail, but they were 
all recently retired (within 5 years of the study 
period). Finally, socio economic charac teristics 
might cause residual confounding. However, 
our study population is a group of blue-collar 
workers with fairly homogeneous backgrounds, 
and we adjusted for years of education. Thus, 
social factors are unlikely to affect the results 
we observed in this study.
Conclusion 
We observed a positive relationship between 
SHS exposure, as measured by cotinine levels 
in plasma, and hs-CRP among non smoking 
workers in the trucking industry, although the 
strength of this association depended on the 
cut-points selected for analysis. We found no 
association of plasma cotinine with sICAM-1 
or IL-6. These results may reflect the relative 
half-lives of the measured biomarkers and 
may depend on the methods used to define 
cutoffs of exposures and health effects.
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